Ovid Therapeutics (NASDAQ: OVID) director awarded 65,000 stock options

Rhea-AI Filing Summary

Ovid Therapeutics Inc. director Stelios Papadopoulos received a grant of stock options covering 65,000 shares on February 26, 2026. These options have an exercise price of $0.00 per share, meaning they were awarded at no cost to him when granted.

The option grant will vest in full on February 26, 2027, provided he remains in continuous service with the company through that date. After this grant, he holds options on 65,000 shares directly, aligning his compensation more closely with the company’s future performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider PAPADOPOULOS STELIOS

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	65,000	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 65,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAPADOPOULOS STELIOS

(Last) (First) (Middle)

C/O OVID THERAPEUTICS INC.

441 NINTH AVENUE, 14TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ovid Therapeutics Inc. [ OVID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$1.65	02/26/2026		A		65,000		(1)	02/25/2036	Common Stock	65,000	$0	65,000	D

Explanation of Responses:

1. The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Jeffrey Rona, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OVID director Stelios Papadopoulos report?

Director Stelios Papadopoulos reported receiving stock options for 65,000 Ovid Therapeutics shares. The options were granted at an exercise price of $0.00 per share as equity-based compensation, rather than an open-market stock purchase or sale.

When do Stelios Papadopoulos’s new OVID stock options vest?

The 65,000 Ovid Therapeutics stock options granted to Stelios Papadopoulos vest in full on February 26, 2027. Vesting is conditioned on his continuous service with the company through that date, encouraging longer-term board commitment and alignment with shareholders.

How many OVID stock options does Stelios Papadopoulos hold after this grant?

Following this grant, Stelios Papadopoulos holds stock options on 65,000 Ovid Therapeutics shares. This reflects the newly awarded employee stock option position and represents his reported direct derivative holdings after the February 26, 2026 transaction.

Was the OVID option grant to Stelios Papadopoulos a stock purchase?

No, the transaction was a grant of employee stock options, not a stock purchase. The options were awarded at an exercise price of $0.00 per share as compensation, classified as a grant, award, or other acquisition rather than an open-market buy.

What conditions apply to the OVID options granted to Stelios Papadopoulos?

The Ovid Therapeutics stock options granted to Stelios Papadopoulos vest only if he maintains continuous service through February 26, 2027. If this condition is met, the entire 65,000-share option award becomes exercisable on that vesting date.